Exelixis, Inc.
Exelixis, Inc. (Nasdaq: EXEL) is an oncology company that discovers, develops and commercializes medicines and regimens for cancer care. Its marketed products include CABOMETYX and COMETRIQ, formulations of cabozantinib used to treat several cancers, including renal cell carcinoma, hepatocellular carcinoma and thyroid… From the company’s description.
In fiscal 2026, Exelixis, Inc. reported revenue of $2.32B, up 7.0% from fiscal 2025, and net income of $782.57M. Its operating margin was 37.6%, and operations generated $884.27M in cash. Over the twelve months to Jul 3, 2026, revenue was $2.44B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Exelixis, Inc. does
In the company’s own words
Exelixis, Inc. (Nasdaq: EXEL) is an oncology company that discovers, develops and commercializes medicines and regimens for cancer care. Its marketed products include CABOMETYX and COMETRIQ, formulations of cabozantinib used to treat several cancers, including renal cell carcinoma, hepatocellular carcinoma and thyroid cancers; COTELLIC (cobimetinib), marketed with Genentech for certain advanced melanomas; and MINNEBRO (esaxerenone), licensed to Daiichi Sankyo for hypertension in Japan. Exelixis commercializes cabozantinib in the United States and relies on Ipsen for markets outside the United States and Japan and Takeda for Japan. Its research and development pipeline includes zanzalintinib, a kinase inhibitor being studied across multiple cancer types, and small-molecule and biotherapeutic candidates, including antibody-drug conjugates and a bispecific antibody. The company reports one operating segment. In fiscal 2025, it generated $2.12 billion in net product revenue from CABOMETYX and COMETRIQ sales. Its website is www.exelixis.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- ALAMEDA, CA
- Fiscal year end
- January
- CIK
- 939767
- SIC
- 2836
Financial performance, year by year
Fiscal 2011–2026 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Exelixis, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Exelixis, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Exelixis, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Exelixis, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Exelixis, Inc.'s last four quarterly filings that the numbers alone won't show?”